BRPI0211191B8 - ensaios baseados em ácido nucléico para se diagnosticar precisamente infecção por parvovírus b19 e inciadores e marcadores para uso nesses ensaios - Google Patents

ensaios baseados em ácido nucléico para se diagnosticar precisamente infecção por parvovírus b19 e inciadores e marcadores para uso nesses ensaios

Info

Publication number
BRPI0211191B8
BRPI0211191B8 BRPI0211191A BR0211191A BRPI0211191B8 BR PI0211191 B8 BRPI0211191 B8 BR PI0211191B8 BR PI0211191 A BRPI0211191 A BR PI0211191A BR 0211191 A BR0211191 A BR 0211191A BR PI0211191 B8 BRPI0211191 B8 BR PI0211191B8
Authority
BR
Brazil
Prior art keywords
assays
parvovirus
nucleic acid
markers
infection
Prior art date
Application number
BRPI0211191A
Other languages
English (en)
Other versions
BRPI0211191B1 (pt
BR0211191A (pt
Inventor
Pichuantes Sergio
Shyamala Venkatakrishna
Original Assignee
Chiron Corp
Grifols Worldwide Operations Ltd
Novartis Vaccines & Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Grifols Worldwide Operations Ltd, Novartis Vaccines & Diagnostics Inc filed Critical Chiron Corp
Publication of BR0211191A publication Critical patent/BR0211191A/pt
Publication of BRPI0211191B1 publication Critical patent/BRPI0211191B1/pt
Publication of BRPI0211191B8 publication Critical patent/BRPI0211191B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

"ensaios baseados em ácido nucléico para se diagnosticar precisamente infecção por parvovírus b19 e iniciadores e marcadores para uso nesses ensaios". são revelados iniciadores e marcadores de parvovírus b19 humano derivados de regiões conservadas do genoma do parvovírus b19. também são revelados ensaios baseados em ácido nucléico usando os iniciadores e marcadores.
BRPI0211191A 2001-06-28 2002-06-28 ensaios baseados em ácido nucléico para se diagnosticar precisamente infecção por parvovírus b19 e inciadores e marcadores para uso nesses ensaios BRPI0211191B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30207701P 2001-06-28 2001-06-28
US36595602P 2002-03-19 2002-03-19
US36922402P 2002-03-29 2002-03-29
PCT/US2002/020684 WO2003002753A2 (en) 2001-06-28 2002-06-28 Diagnostic assays for parvovirus b19

Publications (3)

Publication Number Publication Date
BR0211191A BR0211191A (pt) 2006-05-23
BRPI0211191B1 BRPI0211191B1 (pt) 2015-09-15
BRPI0211191B8 true BRPI0211191B8 (pt) 2021-07-27

Family

ID=28794978

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0211191A BRPI0211191B8 (pt) 2001-06-28 2002-06-28 ensaios baseados em ácido nucléico para se diagnosticar precisamente infecção por parvovírus b19 e inciadores e marcadores para uso nesses ensaios

Country Status (20)

Country Link
US (2) US6936442B2 (pt)
EP (1) EP1537235B1 (pt)
JP (5) JP2005511004A (pt)
KR (2) KR100944674B1 (pt)
CN (1) CN1324147C (pt)
AU (2) AU2002318450B2 (pt)
BG (1) BG66283B1 (pt)
BR (1) BRPI0211191B8 (pt)
CA (2) CA2451756A1 (pt)
CZ (1) CZ308201B6 (pt)
ES (1) ES2537549T3 (pt)
HK (1) HK1080516B (pt)
HU (1) HU230244B1 (pt)
MX (1) MXPA03011802A (pt)
NO (1) NO337901B1 (pt)
NZ (1) NZ530602A (pt)
PL (1) PL210849B1 (pt)
RU (1) RU2301263C2 (pt)
SK (1) SK15752003A3 (pt)
WO (1) WO2003002753A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1421095B1 (en) 2001-08-31 2013-10-09 Gen-Probe Incorporated Assay for detection of human parvovirus b19 nucleic acid
US7956175B2 (en) 2003-09-11 2011-06-07 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
WO2005071401A2 (en) * 2004-01-15 2005-08-04 Chiron Corporation Homogeneous multiplex assay for nucleic acid targets
WO2006031608A2 (en) * 2004-09-10 2006-03-23 Focus Diagnostics, Inc. Methods and compositions for detecting erythrovirus genotypes
WO2006137939A2 (en) * 2004-11-09 2006-12-28 Gen-Probe Incorporated Compositions and methods for detecting group a streptococci
US7572584B2 (en) * 2005-06-02 2009-08-11 The United States Of America As Represented By The U.S. Environmental Protection Agency Species-specific primer sets and identification of species-specific DNA sequences using genome fragment enrichment
US8058000B2 (en) 2005-06-02 2011-11-15 The United States Of America As Represented By The U.S. Environmental Protection Agency Species-specific primer sets and identification of species-specific DNA sequences using genome fragment enrichment
DE102006034844B3 (de) * 2006-07-27 2007-12-06 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Zusammensetzungen und Verfahren zur Amplifikation von Hepatitis A-Viren (HAV) und/oder Parvoviren B19 (PB19) mittels Multiplex-PCR
EP2121913A2 (en) * 2007-01-16 2009-11-25 Talecris Biotherapeutics, Inc. Human erythrovirus
AU2008266120B2 (en) * 2007-06-14 2013-06-20 The Board Of Regents For Oklahoma State University Vaccines containing canine parvovirus genetic variants
WO2009038840A2 (en) * 2007-06-14 2009-03-26 Ibis Biosciences, Inc. Compositions for use in identification of adventitious contaminant viruses
US8227583B2 (en) * 2007-06-14 2012-07-24 The Board Of Regents For Oklahoma State University Vaccines containing canine parvovirus genetic variants
WO2010011002A1 (en) * 2008-07-23 2010-01-28 Industry-Academic Cooperation Foundation Gyeongsang National University Method and system for diagnosing virus
EP3118208A1 (en) 2009-02-26 2017-01-18 Gen-Probe Incorporated Assay for detection of human parvovirus nuleic acid
US9598739B1 (en) 2009-03-13 2017-03-21 Grifols Therapeutics Inc. Human erythrovirus
BR112012025364A2 (pt) 2010-04-07 2015-09-22 Novartis Ag método para geração de partícula semelhante a vírus de parvovírus b19
JP6150795B2 (ja) 2011-07-15 2017-06-28 ジェン−プロウブ インコーポレイテッド シングルプレックス又はマルチプレックスアッセイにおいてヒトパルボウイルス核酸を検出及びａ型肝炎ウイルス核酸を検出するための組成物及び方法
CN103451320B (zh) * 2013-08-09 2015-05-06 中国人民解放军军事医学科学院野战输血研究所 人细小病毒B19三种基因型的实时荧光定量PCR检测方法及其通用检测引物、TaqMan探针与试剂盒
US9410172B2 (en) * 2013-09-16 2016-08-09 General Electric Company Isothermal amplification using oligocation-conjugated primer sequences
WO2015138424A1 (en) 2014-03-10 2015-09-17 University Of Louisville Research Foundaton, Inc. Compositions and methods for treating, including preventing, parvovirus infections and related diseases
CN103820581B (zh) * 2014-03-17 2016-01-13 成都蓉生药业有限责任公司 一种检测人细小病毒b19的试剂盒和方法
JP6414409B2 (ja) * 2014-07-29 2018-10-31 株式会社微生物化学研究所 弱毒化パルボウイルスおよび弱毒化パルボウイルスを用いたワクチン
BR112017009321B1 (pt) * 2014-11-05 2024-03-05 King George's Medical University Sonda, mistura reacional, e, kit de teste
TW202523853A (zh) * 2015-03-27 2025-06-16 美商再生元醫藥公司 偵測生物污染物之組成物及方法
CN105158471A (zh) * 2015-08-24 2015-12-16 北京中检安泰诊断科技有限公司 人细小病毒B19型IgM抗体检测试剂盒及其制备方法
CN114410836B (zh) * 2021-12-17 2024-03-01 上海交通大学医学院附属仁济医院 一种集样本处理、核酸提取及多重恒温扩增一体化的检测人细小病毒b19的试剂盒和方法
CN116769971A (zh) * 2023-07-24 2023-09-19 苏州天隆生物科技有限公司 检测人细小病毒b19的双靶标引物探针组、试剂盒及检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516630A (en) 1983-09-30 1996-05-14 The United States Of America As Represented By The Department Of Health And Human Services Methods of detecting hepatitis A virus
US5283174A (en) 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
CA2020958C (en) * 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US6287815B1 (en) * 1989-09-14 2001-09-11 Rijksuniversiteit Te Leiden Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines
NL8902301A (nl) 1989-09-14 1991-04-02 Rijksuniversiteit Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins.
US6204044B1 (en) * 1989-09-14 2001-03-20 Caroline Sarah Brown Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines
DE4003826C2 (de) 1990-02-08 1995-11-23 Mikrogen Molekularbiol Entw Peptide der Kapsidproteine VP1 oder VP2 des Parvovirus B19
WO1994010294A1 (en) 1992-10-23 1994-05-11 New York University Human monoclonal antibodies to human parvovirus and methods of making and using thereof
US5449608A (en) 1993-03-22 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Parvovirus B19 receptor and parvovirus B19 detection
JPH06293798A (ja) 1993-04-06 1994-10-21 Shin Etsu Chem Co Ltd ヒトパルボウイルスｂ１９のエピトープ関連ペプチド
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
AU3698595A (en) 1994-09-22 1996-04-09 Hans Wolf Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19
US6004044A (en) * 1995-05-03 1999-12-21 Itt Cannon, Inc. Optoelectric connector
JPH0910000A (ja) 1995-06-26 1997-01-14 Nippon Sekijiyuujishiya ヒトパルボウイルスの検出方法及びそのための試薬
WO1997018327A1 (fr) * 1995-11-13 1997-05-22 Shionogi & Co., Ltd. Diagnostic des maladies associees aux spasmes coronariens
AU6267596A (en) 1995-12-14 1997-07-03 Steritech, Inc. Inactivation of non-enveloped virus
US6094338A (en) * 1997-07-09 2000-07-25 Mitsubishi Chemical Corporation Electric double-layer capacitor
WO1999018227A1 (en) 1997-10-08 1999-04-15 Advanced Research And Technology Institute Chimeric parvovirus-based recombinant vector system that specifically targets the erythroid lineage
DE19752898A1 (de) 1997-11-28 1999-08-05 Centeon Pharma Gmbh Verfahren zum Nachweis hoher Vierenkonzentrationen im Blutplasma und/oder Blutserum mittels der Polymerasekettenreaktion
AU758463B2 (en) * 1998-02-04 2003-03-20 Applied Biosystems, Llc Determination of a genotype of an amplification product at multiple allelic sites
RU2146372C1 (ru) * 1998-04-16 2000-03-10 Гематологический научный центр РАМН Способ определения парвовируса б19
US6238860B1 (en) * 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6642033B1 (en) * 1999-07-20 2003-11-04 V.I. Technologies, Inc. Nucleic acids for detecting parvovirus and methods of using same
AU781570B2 (en) * 1999-07-23 2005-06-02 Gen-Probe Incorporated Polynucleotide amplification method

Also Published As

Publication number Publication date
CA2451756A1 (en) 2003-01-09
EP1537235A2 (en) 2005-06-08
PL368049A1 (en) 2005-03-21
NO20035732L (no) 2004-02-27
HK1080516A1 (en) 2006-04-28
NZ530602A (en) 2006-02-24
BRPI0211191B1 (pt) 2015-09-15
CZ20033516A3 (cs) 2005-02-16
CN1636071A (zh) 2005-07-06
RU2301263C2 (ru) 2007-06-20
MXPA03011802A (es) 2004-04-02
SK15752003A3 (sk) 2005-01-03
JP2014061007A (ja) 2014-04-10
KR100888377B1 (ko) 2009-03-13
US20030170612A1 (en) 2003-09-11
NO20035732D0 (no) 2003-12-19
EP1537235B1 (en) 2015-04-01
PL210849B1 (pl) 2012-03-30
EP1537235A4 (en) 2007-10-03
AU2002318450B2 (en) 2007-11-22
BR0211191A (pt) 2006-05-23
CZ308201B6 (cs) 2020-02-26
WO2003002753A2 (en) 2003-01-09
NO337901B1 (no) 2016-07-04
HUP0600779A3 (en) 2010-03-29
US6936442B2 (en) 2005-08-30
JP2009011324A (ja) 2009-01-22
US20050221300A1 (en) 2005-10-06
JP2012075440A (ja) 2012-04-19
CA2779653C (en) 2014-08-19
HK1080516B (zh) 2008-01-25
RU2004102205A (ru) 2005-06-10
ES2537549T3 (es) 2015-06-09
KR20090003370A (ko) 2009-01-09
AU2007231822A1 (en) 2007-11-29
BG108526A (bg) 2004-09-30
AU2007231822B2 (en) 2011-01-27
JP6026401B2 (ja) 2016-11-16
HUP0600779A2 (en) 2007-01-29
CA2779653A1 (en) 2003-01-09
BG66283B1 (bg) 2013-01-31
HU230244B1 (hu) 2015-11-30
JP2016182149A (ja) 2016-10-20
KR20050119220A (ko) 2005-12-21
WO2003002753A3 (en) 2005-04-14
JP2005511004A (ja) 2005-04-28
KR100944674B1 (ko) 2010-03-04
CN1324147C (zh) 2007-07-04

Similar Documents

Publication Publication Date Title
BRPI0211191B8 (pt) ensaios baseados em ácido nucléico para se diagnosticar precisamente infecção por parvovírus b19 e inciadores e marcadores para uso nesses ensaios
BRPI0414313A (pt) inibidores de citocinas
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
EA200000840A1 (ru) Антивирусные производные пиримидина
EP1767546A4 (en) AN ANGIOGENESIS INHIBITING CHIMERIC PROTEIN AND ITS USE
BR0215405A (pt) Composições e processos de uso de collajolie
BRPI0414062B8 (pt) uso de ciclosporinas modificadas para o tratamento de distúrbios por hcv
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
TR200201187T2 (tr) Ters transkriptazın inhibitörleri olarak benzofenonlar
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
BR0014470A (pt) Inibidores de fab i
NO20040322L (no) Virus-polymerase-inhibitorer
ATE332903T1 (de) Kondensierte pyridoindolderivate
BR0306927A (pt) Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv
ATE302776T1 (de) Kondensierte pyridoindolderivate
BR0111393A (pt) Métodos de tratamento de doenças virais com il-18 e suas combinações
BR0208987A (pt) Composto tricìclicos úteis como inibidores de transcriptase reserva de hiv
NO20025461D0 (no) Nye formuleringer av <alfa>-(2,4-disulfofenyl)-N-tert- butylnitron
BRPI0414199A (pt) inibidores de entrada do vìrus hiv
BR0316544A (pt) Compostos calcilìticos
BRPI0408899A (pt) compostos benzo[1,2,5]tiadiazol
BR0114709A (pt) Métodos para a preparação de bifenil isoxazol sulfonamidas
RU2000118409A (ru) Антимутагенное средство
AU2003296820A8 (en) Epitopic peptides of the thyroperoxidase enzyme, compositions containing same and uses thereof

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US)

Free format text: ALTERADO DE: CHIRON CORPORATION

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/06/2002, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2676 DE 19-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.